Publications de Karim Laurent Gariani

Integrative systems analysis identifies genetic and dietary modulators of bile acid homeostasis

Johan Auwerx, Kristina Schoonjans, Alessia Perino, Xiaoxu Li, Giacomo Vincenzo Giorgio Von Alvensleben, Hao Li, Maroun Bou Sleiman, Karim Laurent Gariani, Laura Alejandra Velazquez Villegas, Ludger Jan Elzuë Goeminne

Bile acids (BAs) are complex and incompletely understood enterohepatic-derived hormones that control whole-body metabolism. Here, we profiled postprandial BAs in the liver, feces, and plasma of 360 chowor high-fat-diet-fed BXD male mice and demonstrated th ...

Cell Press2022

Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans

Johan Auwerx, Karim Laurent Gariani

Context: Elevating nicotinamide adenine dinucleotide (NAD+) levels systemically improves metabolic health, which can be accomplished via nicotinamide riboside (NR). Previously, it was demonstrated that NR supplementation in high-fat-diet (HFD)-fed mice dec ...

ENDOCRINE SOC2021

Nicotinamide Pathway-Dependent Sirt1 Activation Restores Calcium Homeostasis to Achieve Neuroprotection in Spinocerebellar Ataxia Type 7

Johan Auwerx, Karim Laurent Gariani

Sirtuin 1 (Sirt1) is a NAD(+)-dependent deacetylase capable of countering age-related neurodegeneration, but the basis of Sirt1 neuroprotection remains elusive. Spinocerebellar ataxia type 7 (SCA7) is an inherited CAG-polyglutamine repeat disorder. Transcr ...

2020

De novo NAD(+) synthesis enhances mitochondrial function and improves health

Johan Auwerx, Kristina Schoonjans, Dongryeol Ryu, Elena Katsyuba, Adrienne Joëlle Laurence Mottis, Karim Laurent Gariani, Marika Olga Zietak

Nicotinamide adenine dinucleotide (NAD(+)) is a co-substrate for several enzymes, including the sirtuin family of NAD(+)-dependent protein deacylases. Beneficial effects of increased NAD(+) levels and sirtuin activation on mitochondrial homeostasis, organi ...

NATURE PUBLISHING GROUP2018

An Integrated Systems Genetics and Omics Toolkit to Probe Gene Function

Johan Auwerx, Kristina Schoonjans, Stephan Morgenthaler, Hao Li, Maroun Bou Sleiman, Xu Wang, Vincenzo Sorrentino, Hongbo Zhang, Peiling Luan, Tao Lin

2018

Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes

Johan Auwerx, Maroun Bou Sleiman, Evan Graehl Williams, Karim Laurent Gariani, Pooja Jha, Pedro Moral Quiros

2018

Systems Analyses Reveal Physiological Roles and Genetic Regulators of Liver Lipid Species

Johan Auwerx, Maroun Bou Sleiman, Evan Graehl Williams, Karim Laurent Gariani, Pooja Jha, Léo Aurélio Diserens, Pedro Moral Quiros

2018

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Johan Auwerx, Kristina Schoonjans, Alessia Perino, Dongryeol Ryu, Vera Monica Lemos Da Silva, Elena Katsyuba, Jun Yong Kim, Hongbo Zhang, Pooja Jha, Keir Joe Menzies

Background & Aims: To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models o ...

Elsevier Science Bv2017

PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis

Johan Auwerx, Dongryeol Ryu, Wei Wang, Karim Laurent Gariani, Zhou Zhou

Background & Aims: Mitochondria) dysfunction, oxidative stress, inflammation, and metabolic reprograming are crucial contributors to hepatic injury and subsequent liver fibrosis. Poly(ADP-ribose) polymerases (PARP) and their interactions with sirtuins play ...

Elsevier Science Bv2017

The therapeutic role of NAD+ modulation in fatty liver disease

Karim Laurent Gariani

NAFLD encompasses a disease spectrum ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and finally cirrhosis, which predisposes to the development of hepatocellular carcinoma. With no approved pharmacological treatment, NAFLD ...

EPFL2017